` 6622 (Zhaoke Ophthalmology Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

6622
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Zhaoke Ophthalmology Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +130% compared to the Hang Seng (Hong Kong)'s +31% growth.

Stocks Performance
6622 vs Hang Seng (Hong Kong)

Loading
6622
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
6622 vs Hang Seng (Hong Kong)

Performance Gap Between 6622 and HSI
HIDDEN
Show

Performance By Year
6622 vs Hang Seng (Hong Kong)

Loading
6622
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Zhaoke Ophthalmology Ltd vs Peers

Hang Seng (Hong Kong)
6622
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Zhaoke Ophthalmology Ltd
Glance View

Market Cap
1.7B HKD
Industry
Pharmaceuticals

Zhaoke Ophthalmology Ltd. operates as holding company with interest in providing ophthalmic pharmaceuticals. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2021-04-29. The Company’s products include innovative drugs and generic drugs. The firm ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.

Zhaoke Ophthalmology Ltd Intrinsic Value
HIDDEN
Show
Back to Top